If You Own Occidental Petroleum Stock, Take A Look At This Instead

Occidental Petroleum is working to shrink a debt burden incurred from acquisitions (Anadarko 2019, CrownRock 2024) and agreed to sell OxyChem to Berkshire Hathaway for $9.7 billion to drive its principal debt below $15 billion, freeing capacity to develop its drilling inventory. ConocoPhillips, by contrast, has maintained a strong balance sheet after equity-funded deals and is committing $3.4 billion to three LNG projects plus $8.5–9 billion to the Willow oil project, forecasting an incremental $6 billion of annual free cash flow by 2029 (at $60/bbl) versus $6.1 billion FCF YTD through Q3; management plans top‑quartile dividend growth and continued buybacks. The piece positions Conoco as better poised to grow shareholder value while Occidental’s path to value creation is less clearly articulated.

Analysis

Market structure: ConocoPhillips (COP) is the clear winner — its $3.4B LNG + $8.5–9B Willow investments target an incremental ~$6B annual free cash flow by 2029 (assumes $60/bbl), effectively doubling near-term FCF power versus peers; Occidental (OXY) benefits from deleveraging via the $9.7B OxyChem sale but loses diversification and near-term EBITDA. Competitive dynamics: COP’s balance-sheet-led growth increases pricing and capital-return optionality (higher buybacks/dividend growth), pressuring independents that financed M&A with debt; OXY’s path-to-value depends on execution of drilling returns from its acreage once net debt falls below the ~$15B target. Supply/demand: planned LNG and Willow supply will be incremental to global liquids and gas markets by 2029 and are rate-sensitive to oil/gas prices; a 10% move in oil/gas consensus materially changes project FCF and implied free-cash yields. Cross-asset: stronger COP FCF supports credit spreads tightening (investment-grade bias), lowers implied equity vols on COP, lifts USD-linked project funding demand, and increases oil and LNG forward curve sensitivity — short-dated energy option vol should compress on positive execution updates.

Risk assessment: Tail risks include a >20% sustained oil price drop (to <$48/bbl) that could cut COP’s incremental FCF by >$1–2B by 2029, major Alaska permitting/legal setbacks for Willow, or commodity demand shocks from macro recession. Time horizons: immediate (days-weeks) reaction will be driven by OxyChem deal closing and near-term oil moves; medium-term (6–18 months) depends on COP project capex execution and any OXY asset sales; long-term (2027–2029) is realization of the $6B FCF swing. Hidden dependencies: COP FCF projection is highly linear to $/bbl and LNG/LNG tolling assumptions, while OXY’s rerate hinges on capex discipline and successful conversion of acreage to high IRR wells after deleveraging. Catalysts: OxyChem close date, COP Willow FID/first-oil milestones, quarterly FCF beats/misses and oil price moves around $55–65/bbl.

Trade implications: Direct play — establish a 2–3% long position in COP equity sized to portfolio risk, targeting re-rate if COP delivers incremental FCF trajectory; complement with a 0.5–1% position in COP Jan 2027 LEAP calls to lever optionality while capping downside. Relative play — pair trade long COP (1.5%) / short OXY (1.0%) to express balance-sheet and execution dispersion; increase short OXY if net-debt/EBITDA remains >2.0x after OxyChem close. Options — sell near-term covered calls on COP after a 10–15% pop to fund 12–18 month call spreads (buy Jan 2027 calls, sell Jan 2027 higher-strike calls) to capture the 2029 FCF re-rating while limiting premium outlay. Sector rotation — overweight integrated and LNG-exposed names (COP, selected midstream contractors) and underweight chemicals-exposed equities until OXY’s post-sale capital allocation is explicit.

Contrarian angles: Consensus understates that OXY’s removal of OxyChem could create a cleaner upstream pure-play that, if acreage converts at mid-teens IRRs, could re-rate materially once debt targets are met — watch upstream well-level IRR data. Reaction may be underdone on COP execution risk: project delays or +20% capex overruns would compress the touted $6B FCF, so the market may reprice quickly on any slippage. Historical parallels: post-M&A deleveragings (e.g., Anadarko-era integrations) show multi-quarter valuation disconnects before rerating — active monitoring of quarterlies can capture swings. Unintended consequences: Berkshire’s large stake and the OxyChem sale may reduce float and increase activist/insider dynamics, making liquidity and volatility risks higher for OXY holders.

Key Decisions for Investors

• Establish a 2–3% long position in ConocoPhillips (COP) equity now to capture the $6B incremental FCF thesis by 2029; add up to 0.5–1% notional in COP Jan 2027 LEAP calls as optional upside, and average down if Brent < $55 for a 10% additional purchase.
• Implement a pair trade: long COP (1.5% portfolio) and short OXY (1.0%) to express balance-sheet and execution divergence; widen the short to 1.5% if OXY net debt/EBITDA remains >2.0x after the OxyChem close or OXY fails to announce a clear drilling-capex-driven buyback plan within 90 days of close.
• Avoid new outright long positions in OXY until the OxyChem sale closes and Occidental reports net debt < $15B or FCF yield >7% (re-evaluate at that point); consider buying OXY Jan 2026 out-of-the-money puts (cost <1% notional) as tail-hedge if you retain exposure.
• If COP trades up >12% on execution news, sell covered calls to lock gains and use proceeds to purchase a Jan 2027 call spread (buy lower strike, sell higher strike) to maintain upside to 2029 FCF delivery at lower cost.